Levact regulatory update

The U.K.'s NICE issued final guidance recommending the use of Levact bendamustine from Mundipharma as a first-line treatment for patients with

Read the full 217 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE